Rigel Pharmaceuticals to Present Innovations at Jefferies Global Healthcare Conference 2025

Rigel Pharmaceuticals Prepares for Key Presentation at Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc., based in South San Francisco, is set to showcase its advancements in hematologic disorders and cancer therapies at the upcoming Jefferies Global Healthcare Conference. Scheduled for November 18, 2025, at 10:00 a.m. GMT, the presentation will be led by President and CEO Raul Rodriguez. This event highlights Rigel’s dedication to innovation in the biotechnology sector, as the company seeks to address the pressing health needs of patients suffering from serious medical conditions. The live webcast of the presentation will be accessible via the Investor Relations section of Rigel's website, allowing stakeholders to engage with the company's developments.

As a company established in 1996, Rigel has built a solid foundation with a focus on improving patient outcomes through both marketed products and a robust pipeline of potential treatments. The upcoming presentation at the Jefferies conference is an opportunity for Rigel to articulate its strategic vision and pipeline advancements to a global audience of investors and healthcare professionals. By participating in such high-profile events, Rigel not only enhances its visibility within the competitive biotech landscape but also reinforces its commitment to innovation and patient care.

The biotechnology industry is rapidly evolving, with companies like Rigel leading the charge in developing therapies for complex diseases. This presentation serves as an important platform for Rigel to share its progress and future directions, potentially attracting new partnerships and investment opportunities. The company’s emphasis on addressing unmet medical needs positions it strategically to contribute meaningfully to advancements in healthcare.

In addition to the conference presentation, Rigel Pharmaceuticals continues to engage with its stakeholders through its website, which provides comprehensive information about its product offerings and ongoing research initiatives. Media inquiries can be directed to David Rosen from Argot Partners, while investors are encouraged to connect with Rigel's investor relations team for further insights. Rigel’s ongoing commitment to innovative healthcare solutions underscores its significance within the biotechnology sector.